Xenon Pharmaceuticals (XENE) Invested Capital (2017 - 2020)

Xenon Pharmaceuticals (XENE) has 4 years of Invested Capital data on file, last reported at $15.5 million in Q1 2020.

• On a quarterly basis, Invested Capital changed 0.0% year-over-year to $15.5 million in Q1 2020; TTM through Dec 2020 was $15.5 million, a 75.0% decrease from a year earlier, with the FY2019 full-year figure at $15.5 million, changed 0.0% from the prior year.
• Invested Capital for Q1 2020 stood at $15.5 million, roughly flat from $15.5 million in the prior quarter.
• Over the last five years, Invested Capital for XENE reached as high as $15.5 million in Q4 2018 and fell as low as $1.4 million in Q1 2018.
• Historically, Invested Capital has averaged $11.8 million across 4 years, with a median of $15.5 million in 2018.
• On a YoY basis, Invested Capital climbed as much as 1007.14% in 2019 and fell as far as 0.0% in 2019.
• Year by year, Invested Capital stood at $7.0 million in 2017, then jumped by 121.43% to $15.5 million in 2018, then changed by 0.0% to $15.5 million in 2019, then changed by 0.0% to $15.5 million in 2020.
• Per Business Quant data, the three most recent Invested Capital figures were $15.5 million in Q1 2020, $15.5 million in Q4 2019, and $15.5 million in Q3 2019.